These agents act by reprogramming the tumor microenvironment—reducing VEGF-driven immunosuppression, altering tumor-associated macrophage (TAM) polarization, and normalizing vasculature—thereby enhancing immune cell infiltration and checkpoint sensitivity. The gene discussed is VEGFA; the disease is neoplasm.